In hematopoiesis, C/EBPA(CAAT/enhancer binding proteins alpha) is a key factor in driving the development of myeloid cells through interacting with a variety of factors(including c-Myc, PU.1 and microRNAs), and mutations of C/EBPA have been observed in about 10% of patients with acute myeloid leukemia (AML) [27, 28]. The gene discussed is SPI1; the disease is acute myeloid leukemia.